Drug Trial Radar · NCT06389877
A Study to Evaluate the Safety and Efficacy of BEAM-302 in Adult Patients With Alpha-1 Antitrypsin Deficiency (AATD)
Last checked: Nov 19, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
192
Planned (sponsor's estimate)
Start
Jun 19, 2024
Primary completion
May 2028
Study completion May 2030
Sponsor
- Lead sponsor
- Beam Therapeutics Inc.Industry
- Sponsor type
- Industry
- First posted
- Apr 29, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1/2, multicenter, open-label study conducted in 3 parts (Part A, Part B, and Part C) to evaluate the safety, tolerability, PK/PD, and efficacy of BEAM-302 in adult patients with AATD-associated lung disease and/or liver disease. Parts A and B are designed to evaluate safety and tolerability and identify the optimal biological dose (OBD) in patients with AATD-associated lung disease (Part A) and/or liver disease (Part B), with optional expansion cohorts to further evaluate a potential OBD. Part C is designed to demonstrate the efficacy and safety of BEAM-302 at the OBD in patients with AATD-associated lung disease with or without liver disease in the pivotal cohort.
Conditions
- Alpha 1-Antitrypsin Deficiency
Interventions
BEAM-302Drug
BEAM-302 is a lipid nanoparticle (LNP)-based therapy for the treatment of patients with AATD
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rates of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)Time frame: 3 years
- Absolute blood levels of total AATTime frame: 3 Years
- Mean total and functional AAT in bloodTime frame: 1 year
Locations
12 sites in 6 countries. Site status is shown where the registry gives one.
Clinical Study Center
Birmingham, Alabama · Recruiting
Clinical Study Center
Boston, Massachusetts · Recruiting
Clinical Study Center
Charleston, South Carolina · Recruiting
Clinical Study Center
Adelaide, Australia · Recruiting
Clinical Study Center
Fitzroy, Australia · Recruiting
Clinical Study Center
Dublin, Ireland · Recruiting
Clinical Study Center
Leiden, Netherlands · Recruiting
Clinical Study Center
Auckland, New Zealand · Recruiting
Clinical Study Center
Hamilton, New Zealand · Recruiting
Clinical Study Center
Birmingham, United Kingdom · Recruiting
Clinical Study Center
London, United Kingdom · Recruiting
Clinical Study Center
Southampton, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.